QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
QQQ   279.76 (-0.79%)
AAPL   145.43 (-0.66%)
MSFT   246.79 (-0.97%)
META   139.07 (+0.06%)
GOOGL   101.42 (+-0.01%)
AMZN   120.30 (-0.54%)
TSLA   238.13 (-1.11%)
NVDA   131.30 (-0.60%)
NIO   14.77 (-7.92%)
BABA   84.32 (-0.08%)
AMD   67.85 (-0.13%)
T   15.32 (-3.83%)
MU   54.62 (-0.20%)
CGC   3.75 (+22.15%)
F   12.36 (-1.20%)
GE   66.22 (-1.81%)
DIS   100.04 (-0.75%)
AMC   7.12 (-2.86%)
PYPL   94.42 (+0.63%)
PFE   43.09 (-2.33%)
NFLX   240.02 (+1.39%)
NASDAQ:CHRS

Coherus BioSciences - CHRS Stock Forecast, Price & News

$9.73
-0.06 (-0.61%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.65
$9.94
50-Day Range
$8.47
$13.87
52-Week Range
$5.60
$19.32
Volume
518,197 shs
Average Volume
1.01 million shs
Market Capitalization
$756.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
95.3% Upside
$19.00 Price Target
Short Interest
Bearish
12.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
0.30mentions of Coherus BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.52) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

352nd out of 1,075 stocks

Biological Products, Except Diagnostic Industry

57th out of 170 stocks

CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

Coherus BioSciences (NASDAQ: CHRS)
Mizuho Securities Keeps Their Buy Rating on Coherus Biosciences (CHRS)
5 Game-Changing Cheap Stocks
These 5 stocks have the potential to outperform the overall market over time because of their future potential. They are well-positioned to deliver a high upside to investors over the next 12 to 18 months. Discover all the details - including name and ticker symbol - here. pixel
Coherus: 2022 Is In Many Ways A Make Or Break Year
5 Game-Changing Cheap Stocks
These 5 stocks have the potential to outperform the overall market over time because of their future potential. They are well-positioned to deliver a high upside to investors over the next 12 to 18 months. Discover all the details - including name and ticker symbol - here. pixel
Can This Small-Cap Biotech 5x Revenue by 2026?
Coherus: Will Its Chinese Gambit Fail?
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
332
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+95.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-287,100,000.00
Pretax Margin
-83.47%

Debt

Sales & Book Value

Annual Sales
$326.55 million
Book Value
$1.27 per share

Miscellaneous

Free Float
68,468,000
Market Cap
$756.26 million
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 67)
    Chairman, Pres & CEO
    Comp: $1.86M
  • Mr. McDavid StilwellMr. McDavid Stilwell (Age 50)
    Chief Financial Officer
    Comp: $756k
  • Mr. Vladimir Vexler Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $778.28k
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Mr. Christopher W. Slavinsky (Age 49)
    Chief Bus. & Legal Officer
  • Cheston Turbyfill
    VP of Communications
  • Ms. Karen Kotz
    Exec. VP of Sales & Strategic Accounts
  • Ms. Rebecca Sunshine (Age 59)
    Chief HR Officer
  • Mr. Michael A. Fleming
    Chief Strategy Officer
  • Mr. Michael Chen
    Sr. VP of Commercial Analytics & Trade













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2022?

4 analysts have issued 1 year target prices for Coherus BioSciences' shares. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they predict the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 95.3% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2022?

Coherus BioSciences' stock was trading at $15.96 at the beginning of the year. Since then, CHRS stock has decreased by 39.0% and is now trading at $9.73.
View the best growth stocks for 2022 here
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. The biotechnology company had revenue of $60.15 million for the quarter, compared to the consensus estimate of $58 million. Coherus BioSciences had a negative net margin of 83.47% and a negative trailing twelve-month return on equity of 422.10%. During the same quarter in the prior year, the firm posted ($0.40) earnings per share.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $9.73.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $756.26 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.